Uptake in the BELVIQ this year was smaller than expected, but continues to be steady. Greater marketing efforts by the major players, and greater demand for an increasingly overweight population, could accelerate the positive sales in future quarters.
Obesity Stocks Focus on Approvals As Arena Pharmaceuticals Goes Global
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts